We are pleased to share that Solid Biosciences has begun dosing patients in the Phase I/II clinical study of its next-generation gene therapy, SGT-003. The study, INSPIRE DUCHENNE, is ongoing at two sites in the US – Nationwide Children’s Hospital in Columbus, Ohio, and UCLA in California. It plans to expand to six sites in North America later this year, and to additional sites in Europe next year.
Click here to read Solid’s Letter to the Duchenne Community.
The Duchenne Research Fund is proud to have funded Solid Biosciences as it became one of the first gene therapy research programmes for Duchenne muscular dystrophy. This led to the IGNITE DMD Phase I/II clinical trial in the United States, using Solid’s first-generation gene therapy candidate SGT-001. Data published from the trial in March 2022 showed patients have improved motor and lung function two years on from receiving the treatment, compared with the declines that would be expected without treatment.
Building on Solid’s significant progress in advancing gene therapy for Duchenne, the company announced its focus on its next-generation gene therapy candidate, SGT-003, which uses a novel next-generation capsid to deliver the microdystrophin protein. In pre-clinical studies of SGT-003 performed in mouse models and in vitro in human Duchenne cell lines, multiple fold increases in microdystrophin expression have been observed, compared with the first-generation candidate.